Overview

Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
To assess the safety of the combination of VX-950, Pegasys and Copegus in subjects with hepatitis C.
Phase:
Phase 2
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Treatments:
Interferon-alpha
Peginterferon alfa-2a
Ribavirin